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Abstract:  24	
Case Series Summary: Feline tuberculosis is an increasingly recognised potential zoonosis of cats. Treatment 25	
is challenging and prognosis can vary greatly between cases. Pulmonary infection requires extended courses of 26	
antibiotics, but methodologies for sensitively monitoring response to treatment are currently lacking.  27	
 28	
In this case series we retrospectively examined the serial computed tomography (CT) findings in nine cats that 29	
had been diagnosed with tuberculosis. Changes in pathology (where applicable to tuberculosis) were correlated 30	
with the clinical presentation of each of the cats, the treatment protocol, plus previous and contemporary 31	
diagnostic investigations.    32	
 33	
This study found that changes in CT findings during the medium to long term management of feline tuberculosis 34	
were highly variable between cats. The majority of cats had reduced pathology at re-examination during anti-35	
tuberculous therapy, but pathology only resolved in a minority of cases. In some cases reoccurrence of 36	
pathology detected by CT imaging preceded clinical relapse, allowing for rapid therapeutic intervention. 37	
 38	
Relevance and Novel Information: When considered in combination with clinical findings, CT studies can 39	
aid in decision making regarding tapering of antibiotic protocols, or reintroduction of therapy in cases of 40	
recurrence or reinfection. These cases also highlight that in some cases, persistent abnormalities can be 41	
detected by CT so complete resolution of CT pathology should not always be a goal in the management of 42	
feline tuberculosis.  43	
		 3	
Introduction 44	
Feline tuberculosis is a highly variable and increasingly recognised disease in domestic pet cats in the British 45	
Isles.1-3 Infection is assumed to be acquired from bites by prey species sustained during hunting, leading to the 46	
most typical clinical presentation of cutaneous lesion/s at “fight and bite sites” with or without regional lymph 47	
node involvement.1-3 Disseminated disease can occur, resulting in non-specific signs related to the respiratory 48	
and/or alimentary tracts giving rise to variable findings on diagnostic imaging investigations.4-7 Thoracic and/or 49	
abdominal pathology can more rarely result from acquisition of disease through inhalation or ingestion.1,5 The 50	
radiological and computed tomography (CT) abnormalities associated with disseminated mycobacterial 51	
infection have previously been described.2,4,7     52	
Advocated treatment protocols for feline tuberculosis typically consisted of an initial and a continuation phase.8 53	
The initial phase combines three antibiotic drugs lasting for two months, while the continuation phase comprises 54	
of two drugs for a further four months.8 However, it is possible that treating with all three drugs until two 55	
months after apparent clinical resolution, which typically results in four to six months of treatment, may result 56	
in a better clinical outcome (DGM and COH, unpublished data, 2016).  57	
Prognosis varies depending on the species of mycobacterium involved, the extent and severity of disease, and 58	
the compliance and tolerance of the patient to medication.1,6 While many cases respond favorably to therapy, 59	
resulting in apparent cure or long term remission, other patients either fail to respond or go on to develop 60	
recurrence of signs following apparently successful treatment.1,6 61	
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 62	
In order to assist clinical decision making by veterinary surgeons and owners, a reliable method is needed to 63	
monitor the disease at all stages of management. The use of CT has already been shown to be a valuable tool in 64	
the initial diagnosis.7 In this report, we describe the use of CT during the medium and long term follow-up of 65	
tuberculous disease in nine cats between June 2010 and May 2016. Table 1 shows signalment and summary 66	
data for all nine cases detailed below. 67	
 68	
 69	
 70	
 71	
 72	
 73	
 74	
 75	
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Table 1: Summary details of the nine case of feline tuberculosis where serial CT images were used as part of clinical follow-up 76	
Case 
Number 
Breed Age 
(years) 
Gender Location in 
UK 
Weight 
(kg) at 
initial 
presentation 
Haematology & 
serum biochemistry 
(reference interval) 
FIV / 
FeLV 
status 
Diagnosis Impact of CT evaluations 
1 Oriental 7 MN South 
Scotland 
5 
 
Total calcium 
3.13mmol/L  
(1.95-2.83mmol/L) 
Ionised calcium  
1.75mmol/L  
(1.05-1.45mmol/L) 
Negative M. microti Early re-instigation of 
antibiosis following slight 
clinical deterioration.  
2 DSH 11 FN Central 
Scotland 
3.6 No abnormalities 
detected 
Negative M. microti Pulmonary dissemination 
of tuberculosis diagnosed. 
Mid-term static 
appearance of lesion 
irrespective of antibiotic 
therapy.  
3 Bengal 13 MN South 
Scotland 
5 No abnormalities 
detected 
Negative M. microti Delayed antibiotic 
tapering due to persistent 
abnormalities. 
Early re-instigation of 
antibiosis following slight 
clinical deterioration. 
		 6	
4 British 
Shorthair 
10 MN Cheshire, 
England 
3.8 Hyperglobulinaemia Negative M. bovis Reduction of antibiosis 
with improvement to 
detectable abnormalities. 
5 DSH 7 
months 
MN Bristol, 
England 
2.8 Total calcium  
3.95mmol/L 
(2.30-2.50mmol/L) 
Negative M. microti Discontinuation of 
antibiosis with 
improvement to detectable 
abnormalities. 
6 DSH 3 FN West 
Midlands, 
England 
4.1 No abnormalities 
detected 
Negative Tuberculosis 
complex 
Reduction of antibiosis 
with early improvement to 
detectable abnormalities. 
7 DSH 7 MN South 
Scotland 
5 No abnormalities 
detected 
Negative M. microti Reduction of antibiosis 
with improvement to 
detectable abnormalities. 
8 Burmilla 8 ME South 
Scotland 
4.6 No abnormalities 
detected 
Negative M. microti Discontinuation of 
antibiosis with 
improvement to detectable 
abnormalities. 
9 DSH 7 MN Central 
Scotland 
5.7 No abnormalities 
detected 
Negative M. microti Continuation of antibiosis 
with partial improvement 
to detectable 
abnormalities. 
Legend: DSH: domestic short hair, MN: male neutered, FN: female neutered, ME: male entire, FIV: feline immunodeficiency 77	
virus, FeLV: feline leukaemia virus.  78	
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Case Series Description 80	
Case 1 81	
Case 1 initially presented with anorexia and weight loss. Mild mandibular lymphadenomegaly and harsh lung 82	
sounds were noted on physical examination. Thoracic radiographs revealed a diffuse structured interstitial lung 83	
pattern; CT was not performed as the clinic did not have on-site access to CT at this time. The feline interferon 84	
gamma (IFN-g)	 release assay (IGRA) was performed by Biobest Laboratories, Edinburgh, and indicated 85	
infection with Mycobacterium microti.8 The cat was treated with a triple antibiotic protocol of rifampicin 86	
[generic, Mylan, Herts] (10mg/kg) 50mg PO q24h, marbofloxacin [Marfloquin, Virbac] (3mg/kg) 15mg PO 87	
q24h, and azithromycin [Zithromax, Pfizer] (6mg/kg) 30mg PO q24h for two months as the induction treatment 88	
phase; marbofloxacin was then discontinued and the remaining antibiotics continued for the maintenance phase. 89	
After six months, clinical remission from disease was achieved; serum calcium concentration was within the 90	
reference interval and repeat radiographs revealed no abnormalities, so antibiosis was stopped. 91	
Eleven months after antibiotic treatment had been discontinued, the cat represented with a recurrence of lethargy 92	
and anorexia, with normal lung sounds but reduced thoracic compression. Body weight had increased to 6.2kg. 93	
A recurrence of hypercalcaemia was noted (ionised calcium 1.75 mmol/l) and serum 25-hydroxyvitamin D 94	
concentration was low (46 pg/ml, RI 14.9-61.0ng/ml). Full-body CT was performed using a VetMouseTrap 95	
device, revealing mild tracheobronchial, mediastinal and mesenteric lymphadenomegaly and a diffuse, 96	
moderate reticulonodular lung pattern (Figure 1a). Recurrence or reinfection of tuberculosis was assumed and 97	
triple antibiotic therapy was reinstated (drugs and doses as above, dosed for a 6kg cat). In addition, calcitriol 98	
supplementation was given at a dose of 2ng/kg PO q24h. Three months later the cat was reassessed, and clinical 99	
examination and whole-body CT were normal (Figure 1b). On the basis of completing three months of triple 100	
antibiotic therapy and resolution of clinical signs, treatment was changed to pradofloxacin (Veraflox tablets 101	
		 9	
Bayer) [4mg/kg] 25mg PO q24h, which was given as an antimicrobial monotherapy for six months with 102	
calcitriol supplementation as previously described. Two further CT examinations were performed, at four and 103	
six months after disease recurrence, and were normal. Eleven months after recurrence, after two months off 104	
pradofloxacin, the cat was represented as the owner observed a mildly increased sleeping respiratory rate 105	
(21bpm; this cats normal sleeping respiratory rate was <20bpm). Despite a normal clinical examination, a CT 106	
scan demonstrated a diffuse mild reticular lung pattern with areas of ground glass opacity (Figure 1c); the serum 107	
calcium concentration was increased and serum 25-hydroxyvitamin D concentration was low. Triple antibiotic 108	
therapy was restarted (rifampicin and azithromycin, dosed as above, plus pradofloxacin [Veraflox liquid, Bayer] 109	
[~5mg/kg] 30mg PO q24h), and calcitriol treatment was restarted at [2ng/kg] 12.5mcg PO q24h (body weight 110	
6.5kg). After two-months of treatment repeat CT examination was normal. Due to the history of several episodes 111	
of disease it was recommended that the triple antibiotic therapy be continued for a further four months, followed 112	
by three months of double antibiotic therapy (azithromycin and pradofloxacin, dosed as above). The cat 113	
remained clinically normal throughout this period and treatment was discontinued a total of 20 months after the 114	
initial recurrence. Two months later another IGRA returned a negative result and the serum calcium and 25-115	
hydroxyvitamin D concentrations were within normal limits. A further episode of mycobacterial 116	
recurrence/reinfection occurred after eight months without treatment. The cat was again re-presented following 117	
observation of a mildly increased sleeping respiratory rate (23bpm; body weight 7.1kg). Whole body CT 118	
demonstrated mild diffuse thoracic and abdominal lymphadenomegaly, and a diffuse but patchy, mild to 119	
moderate reticulonodular lung pattern. A repeated IGRA was positive and consistent with M. microti infection. 120	
Triple antibiotic therapy was prescribed for three months (rifampicin, pradofloxacin and azithromycin, dosed 121	
as above, for a 7kg cat), followed by double antibiotic therapy for a further nine months (pradofloxacin and 122	
azithromycin, dosed as immediately above). During this period, the cat remained well, and a further four full-123	
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body CT examinations revealed a normal pulmonary parenchymal appearance. Given the normal imaging and 124	
clinical findings throughout this period, antibiotics were discontinued as planned, and the cat remains well 125	
without recurrence of clinical signs over 17 months later, during this time five CT scans revealed no detectable 126	
abnormalities. A timeline of this case is shown in Figure 2.   127	
Case 2 128	
Case 2 was first presented for weight loss and generalised lymphadenomegaly. Radiographs revealed a diffuse 129	
interstitial lung pattern (CT was not available at the clinic at that time). Excisional biopsy of the popliteal lymph 130	
nodes was performed; histopathology revealed a granulomatous lymphadenitis and Zeihl Neelsen (ZN) staining 131	
identified intra-lesional acid-fast bacilli indicative of mycobacterial infection. A triple antibiotic protocol was 132	
instigated (rifampicin [11mg/kg] 40mg PO q24h; marbofloxacin [2.7mg/kg] 10mg PO q24h; clarithromycin 133	
[11mg/kg] 40mg PO q12h) for two months followed by rifampicin and marbofloxacin (same doses) for four 134	
months. Revisits revealed initially static peripheral lymphadenomegaly, which resolved over the four months 135	
of maintenance treatment. Repeat thoracic radiography at the end of the maintenance phase revealed no 136	
abnormalities and treatment was therefore discontinued. Four months following the end of treatment the cat 137	
presented to an emergency clinic with acute respiratory signs. Laryngeal swelling was identified and following 138	
stabilisation with corticosteroids, furosemide, chlorphenamine (all at standard doses), plus additional oxygen, 139	
the laryngeal swelling resolved. Radiography revealed a thoracic mass consistent with an enlarged cranial 140	
mediastinal lymph node. This was confirmed on full body CT examination using a VetMouseTrap device, 141	
which also revealed moderate mineralisation within the mass lesion (Figure 3a). Fine needle aspiration (FNA) 142	
of the mass yielded a non-diagnostic sample whilst an IGRA was consistent with M. microti infection. Given 143	
the previous history of mycobacterial lymphadenitis, with an owner who was reticent to restart triple therapy, 144	
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the cat was started on single antibiotic therapy (pradofloxacin liquid [7mg/kg] 25mg PO q24h) to see if this 145	
might reduce the size of the thoracic mass and so give weight to the diagnosis that it may be tuberculous. One 146	
month later the cat was clinically well and CT revealed a static appearance to the mass. Antibiotic therapy was 147	
discontinued as it did not appear to be effective. Three months later the CT appearance remained unchanged, 148	
and a repeat IGRA was inconclusive. The cat represented the next month with hypersalivation and difficulty 149	
eating. Physical examination revealed thickening of the caudal aspect of the right mandibular ramus, with 150	
loosening of the associated teeth. On CT this lesion was characterised by moderate bone lysis with concurrent 151	
proliferation, moderate regional lymphadenomegaly was noted. The thoracic mass remained static in 152	
appearance, but the surrounding lung had a mild patchy ground glass appearance (Figure 3b). The appearance 153	
of the mandibular lesion was not considered typical for tuberculous osteomyelitis. Biopsy of the mandibular 154	
mass and local lymph nodes resulted in a diagnosis of squamous cell carcinoma with reactive lymphoid 155	
hyperplasia. The owner opted for palliative therapy with meloxicam (Metacam, Boehringer Ingelheim 156	
0.05mg/kg PO q24h), and after three weeks the cat was euthanased. Post mortem examination was performed 157	
and histopathology of the enlarged cranial mediastinal lymph node revealed large numbers of acid-fast bacilli 158	
within the node and the peri-nodal connective tissue. As indicated by CT, granulomatous inflammatory changes 159	
extended into the adjacent pulmonary parenchyma. The lymph node was confirmed to be PCR positive for M. 160	
microti by the Mycobacterial Reference Laboratory, Leeds University Teaching Hospital. A timeline of this 161	
case is shown in Figure 4. 162	
Case 3 163	
Case 3 initially presented with mandibular lymphadenomegaly. Sternal lymphadenomegaly was noted on 164	
thoracic radiography and abdominal ultrasound revealed marked mesenteric lymphadenomegaly and focal 165	
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marked circumferential jejunal thickening; FNA of the mandibular and jejunal lymph nodes and the abnormal 166	
jejunal wall revealed granulomatous inflammation with acid-fast bacilli indicative of mycobacterial infection. 167	
An IGRA was consistent with M. microti infection and the cat was started on triple antibiotic therapy (rifampicin 168	
[10mg/kg] 50mg PO q24h; azithromycin [8mg/kg] 40mg PO q24h; pradofloxacin tablets [5mg/kg] 25mg PO 169	
q24h), plus calcitriol supplementation ([2ng/kg] 10mcg PO q24h). Two months later the cat was clinically well, 170	
although the right mandibular lymph node remained slightly enlarged. A conscious full-body CT examination 171	
using a VetMouseTrap device was performed, revealing improved but persistent mesenteric 172	
lymphadenomegaly. Given the clinical and imaging findings, the triple antibiotic therapy described above was 173	
maintained for another four months, giving a total treatment duration of six months, after which the mandibular 174	
and mesenteric lymph nodes were palpably normal and antibiosis was discontinued (body weight 6.4kg at this 175	
time).  Three months later the cat represented with weight loss, lethargy and inappetence (body weight 6.0kg). 176	
The peripheral lymph nodes were of normal size but harsh inspiratory lung sounds and multiple palpable 177	
abdominal masses were noted. Both abdominal ultrasound and full-body CT were performed, confirming the 178	
presence of marked thoracic and abdominal lymphadenomegaly, and focal marked jejunal thickening as had 179	
been previously described. A diffuse, mild reticulonodular lung pattern was also noted. A FNA of the mesenteric 180	
lymph nodes again revealed granulomatous inflammation with acid fast bacilli. Triple antibiotic therapy was 181	
resumed at the dose rates detailed previously, but despite an initially improved demeanour the cat continued to 182	
lose weight and after five months of treatment was euthanased. Post mortem examination was not performed. 183	
A timeline of this case is shown in Figure 4. 184	
Case 4 185	
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Case 4 initially presented with weight loss, dyspnoea and coughing. Physical examination revealed tachypnoea 186	
(respiratory rate 40bpm), with increased inspiratory and expiratory effort and noise. Thoracic CT examination 187	
revealed a moderate multifocal alveolar pattern with regions of pulmonary cavitation affecting multiple lung 188	
lobes, most marked within the right caudal lobe, and a moderate thoracic lymphadenomegaly (Figure 5a). A 189	
right caudal lung lobectomy was performed and histopathology revealed necrotising and pyogranulomatous 190	
bronchopneumonia; however, no acid fast bacteria were identified. Tissue was submitted for culture and blood 191	
for IGRA, and treatment with marbofloxacin ([2mg/kg] 8mg PO q24h) was started. A good clinical response 192	
was noted in the initial two-month post-operative period; however, tissue culture and IGRA both confirmed 193	
Mycobacterium bovis infection, and a standard triple antibiotic protocol was introduced (marbofloxacin 194	
[2mg/kg] 8mg PO q24h; azithromycin [10mg/kg] 40mg PO q24h; rifampicin [20mg/kg] 80mg PO q24h – 195	
although the dose of rifampicin was high). After two months of triple antibiotic treatment, CT was repeated 196	
revealing residual patchy ground glass opacity, with collapsed cavities within the remaining lung lobes, but 197	
subjectively normal thoracic lymph nodes. Due to the improved pulmonary appearance and the good clinical 198	
condition of the cat, triple antibiotic therapy was reduced to dual therapy (marbofloxacin and rifampicin, dosed 199	
as above). After a further four months, the appearance of the lungs on CT examination was unchanged (Figure 200	
5b) and a repeat IGRA remained positive. Antibiotic treatment was discontinued, and the cat remained well, 201	
with a negative IGRA result obtained six months later. A timeline of this case is shown in Figure 4. 202	
Case 5 203	
Case 5 initially presented with coughing, resting tachypnoea (respiratory rate 55bpm), and exercise intolerance. 204	
Body weight and condition score (1.5/5) were low. Thoracic and abdominal CT examination revealed a diffuse 205	
marked nodular lung pattern with occasional scattered foci of pulmonary mineralisation (Figure 6a), marked 206	
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tracheobronchial lymphadenomegaly and mild peripheral and abdominal lymphadenomegaly. A FNA of lung 207	
tissue revealed marked pyogranulomatous inflammation with acid-fast bacilli and was PCR positive for 208	
Mycobacterium tuberculosis complex organisms. The IGRA suggested infection with M. microti. A standard 209	
antibiotic protocol of two months’ triple therapy (pradofloxacin [~5mg/kg] 15mg PO q24h; azithromycin 210	
[~10mg/kg] 30mg PO q24h; rifampicin [~10mg/kg] 30mg PO q24h) was followed by ongoing double therapy 211	
(azithromycin and rifampicin, dosed as above). At a recheck after eight months of treatment the cat was 212	
clinically normal and had an improved body weight and body condition score (4.4kg and 2.5/5). Thorax CT 213	
revealed only a mild diffuse reticulonodular lung pattern, but scattered pulmonary mineralisation was more 214	
extensive than previously noted (Figure 6b). Antibiotic therapy was discontinued. The cat remained well and 215	
the CT abnormalities were seen to be static at a revisit 12 months later. A timeline of this case is shown in 216	
Figure 4. 217	
Case 6 218	
Case 6 presented with lethargy, intermittent dyspnoea, weight loss, stridor and nasal discharge. Clinical 219	
examination revealed a moderate inspiratory dyspnoea with wheezing on auscultation, bilateral serous nasal 220	
discharge, bilateral renomegaly and bilateral popliteal lymphadenomegaly. A CT examination of the head, 221	
thorax and abdomen revealed an alveolar lung pattern within the right middle and ventral right caudal lung 222	
lobes, with a diffuse moderate reticulonodular pattern, moderate multifocal lymphadenomegaly, mild bone lysis 223	
over the nasal bridge and multiple mass lesions in both kidneys. Nasal biopsies confirmed mycobacterial 224	
infection by histopathology, and was PCR positive for Mycobacterium tuberculosis complex organisms, but the 225	
laboratory was unable to further define the species. A standard antibiotic protocol of two months’ triple therapy 226	
was prescribed (pradofloxacin [~5mg/kg] 20mg PO q24h; azithromycin [~10mg/kg] 40mg PO q24h; rifampicin 227	
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[~10mg/kg] 40mg PO q24h), followed by ongoing double therapy (pradofloxacin and rifampicin, dosed as 228	
above). Two months after the start of antibiotic therapy the cat was clinically well. The CT showed marked 229	
improvements, with residual diffuse mild pulmonary ground glass appearance, mild multifocal 230	
lymphadenomegaly and partial resolution of the renal mass lesions. Antibiotics were discontinued after a six-231	
month course, and the cat remains clinically well 12 months later.  A timeline of this case is shown in Figure 4. 232	
Case 7 233	
Case 7 presented with dysuria due to a well demarcated alopecic skin nodule of 2cm diameter over its prepuce. 234	
Physical examination revealed a mildly elevated resting respiratory rate (48 bpm). An incisional biopsy of the 235	
preputial lesion revealed granulomatous inflammation and rare acid-fast bacilli indicative of mycobacterial 236	
infection. An IGRA was strongly suggestive of an M. microti infection. A CT scan, performed using a 237	
VetMouseTrap device, revealed a focal region of alveolar pattern in the left cranial lung lobe with a diffuse 238	
mild reticulonodular pattern suggestive of pulmonary tuberculosis. The cat was placed on standard triple 239	
antibiotic therapy (pradofloxacin tablets [3mg/kg] 15mg PO q24h; azithromycin [6mg/kg] 30mg PO q24h; 240	
rifampicin [10mg/kg] 50mg PO q24h) for four months. By re-evaluation, the preputial lesion and dysuria had 241	
completely resolved and thoracic CT revealed an improvement in both the focal and diffuse pulmonary changes. 242	
The cat was changed to dual antibiotic therapy (rifampicin and azithromycin, dosed as above), and this was 243	
discontinued after an additional two months; the cat remains clinically well six months later. A timeline of this 244	
case is shown in Figure 4. 245	
Case 8 246	
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Case 8 was presented for investigation of dyspnoea (respiratory rate 60bpm), bilateral mandibular 247	
lymphadenomegaly and palpable abdominal masses. Abdominal ultrasound showed a diffusely heterogeneous 248	
appearance to the spleen and mild generalised abdominal lymphadenomegaly. An exploratory laparotomy was 249	
performed to biopsy the abnormal structures. Histopathological analysis of the spleen and medial iliac lymph 250	
node revealed granulomatous splenitis and reactive lymphoid hyperplasia consistent with mycobacteriosis 251	
although no acid-fast bacteria were seen. Thoracic radiography revealed a severe diffuse mixed bronchial and 252	
nodular pattern with multiple foci of mineralisation in the caudodorsal lung fields. No thoracic 253	
lymphadenomegaly was evident. An IGRA indicated M. microti infection, so triple antibiotic therapy was 254	
instigated for six months (marbofloxacin [2mg/kg] 10mg PO q24h; rifampicin [16mg/kg] 75mg PO q24h; 255	
clarithromycin [8mg/kg] 35mg PO q12h). Re-evaluation after six months revealed that the initial clinical signs 256	
had resolved and a full body CT scan using the VetMouseTrap identified complete resolution of the previously 257	
noted lung pattern and abdominal lymphadenomegaly. Several small mineral foci remained visible within the 258	
lungs which were predominantly, but not exclusively, airway associated. Antibiotic therapy was discontinued 259	
at this point. The cat remained clinically well and at a routine revisit over 33 months later a full body CT was 260	
repeated using the VetMouseTrap. This study revealed normal pulmonary parenchyma and there was no 261	
evidence of lymphadenomegaly. More extensive and more widely distributed predominantly airway-associated 262	
mineralisation was present.  A timeline of this case is shown in Figure 4.  263	
Case 9 264	
Case 9 was presented for investigations into stertorous breathing and a rapidly growing inter-ocular skin lesion. 265	
The CT examination of the head and thorax revealed a soft tissue mass lesion overlying the frontal and nasal 266	
bones with several associated small foci of bone lysis, plus a diffuse but asymmetrical, mixed lung pattern. 267	
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Moderate bronchial and reticulonodular patterns affected the right lung lobes, partial collapse and an alveolar 268	
pattern was noted within the accessory lung lobe, and multiple larger well-defined nodules (some showing 269	
internal mineralisation) were present within the left lung lobes, with more normal appearing parenchyma 270	
surrounding them. There was moderate sternal and cranial mediastinal and marked tracheobronchial 271	
lymphadenomegaly. Histopathology on an incisional biopsy of the soft tissue mass revealed a large mixed 272	
inflammatory cell infiltrate including epitheloid macrophages, suggestive of mycobacteriosis; ZN staining 273	
revealed large numbers of acid fast bacilli which were identified by PCR as M. microti. Triple antibiotic therapy 274	
was instigated for nine months (clarithromycin [11mg/kg] 65mg PO q12h; rifampicin [9mg/kg] 50mg PO q24h; 275	
marbofloxacin [1.8mg/kg] 10mg q24h). Within two months the stertor had resolved and the skin lesion had 276	
reduced in size; by the end of the nine month course of antibiosis all clinical signs had fully resolved. A CT 277	
scan showed improvement but not resolution of the mediastinal and sternal lymphadenopathy and diffuse lung 278	
changes. The left lung nodules had mildly more extensive mineralisation than previously. It was decided to 279	
continue treatment due to the continued presence of pathology and a timeline of this case is shown in Figure 4. 280	
Discussion 281	
The cases presented here are a cohort of cats with conclusive or strong evidence supporting a diagnosis of feline 282	
tuberculosis (culture, PCR and/or IGRA results). In contrast to previously published data on feline tuberculosis, 283	
the cases in this series are predominately M. microti infections, whereas national culture data shows that while 284	
M. microti can be cultured from 19% of cases with histopathological changes indicative of mycobacteriosis, M. 285	
bovis can usually be cultured from 15%.2 The reason for the lack of M. bovis cases is unclear; it may result of 286	
our small sample size, the majority of which lived in regions of the UK where M. microti is more prevalent2, or 287	
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it could indicate an underlying bias towards owners being more likely to treat cats with M. microti-infection 288	
rather than M. bovis, probably due to the higher zoonotic risk associated with the latter organism9.   289	
In line with previous studies, the majority of cats with tuberculosis in this study are males;2 none were found to 290	
be co-infected with the FIV and FeLV, and the median age of cats infected with M. microti was seven years 291	
(range seven months - 13 years), compared to a previously documented median of eight years.2   292	
The cases in this series demonstrated a range of clinical responses following diagnosis and treatment of 293	
disseminated feline tuberculosis, and in each case, repeated CT imaging contributed to decision making in 294	
ongoing clinical management within the context of contemporaneous investigations. It is recognised that the 295	
cases in this study show significant variability both in the use of CT and its timing in relation to treatment. This 296	
largely relates to the multi-centre nature of this study, as decision making varied depending on the preferences 297	
of the primary clinician. 298	
A previous study found a sustained complete remission in only 40% of feline mycobacterial infections;6 299	
however, that study included many cases that were treated with sub-optimal drug regimens (e.g. short courses 300	
of fluoroquinolone monotherapy),6,10 as well as including M. avium infections which are known to be refractive 301	
to treatment due to complex inherent drug resistance patterns.11 Previously advocated treatment protocols for 302	
feline tuberculosis typically consisted of an initial and a continuation phase.9 However, recent studies regarding 303	
multi-drug resistant M. tuberculosis (MDR-TB) in humans have suggested that using at least three and ideally 304	
four antibiotics given in combination throughout treatment significantly reduces the development of 305	
antimicrobial drug resistance.12-15 Recommended first line anti-tuberculosis medications for humans consist of 306	
rifampicin, isoniazid, dihydrostreptomycin, ethambutol and pyrazinamide.16 However, the use of these drugs 307	
does not readily translate into veterinary medicine; isoniazid has been associated with neurological side effects 308	
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in small animals,17 pyrazinamide is ineffective against M. bovis infections18 which comprise approximately 309	
15% of feline mycobacterial infections,2 and dihydrostreptomycin should be reserved for human use.19 310	
Therefore, small animal anti-tuberculosis therapy, when undertaken, should consist of a triple combination of 311	
rifampicin (for its potency and its ability to kill non-replicating [latent] tuberculous Mycobacteria20 312	
[recommended doses 10-15mg/kg PO q24h]), a fluoroquinolone (ideally pradofloxacin as it has better efficacy 313	
against Mycobacteria than older fluoroquinolones, 21,22 and a better safely profile in cats 23 [pradofloxacin 314	
recommended doses 3-7mg/kg PO q24h]) and a macrolide (such as clarithromycin [7-15mg/kg PO q12h] or 315	
azithromycin [5-15mg/kg PO q24h]) for a minimum of three months as standard.9,24 It is recommended that 316	
treatment should be given for two to three months after apparent clinical resolution, which typically results in 317	
four to six months of treatment.9,24 The efficacy of combination long-term treatment is supported by the cases 318	
in this series, as all were treated with either two or three antibiotics for at least six months; only one of the cats 319	
died from tuberculosis, and another was found to have latent tuberculosis after euthanasia for an unrelated 320	
disease. This gives a sustained complete remission rate of eight of nine cases (~90% remission), which is much 321	
higher than the 40% previously reported.6 This is much more in line with our recent experiences, as following 322	
the introduction of sustained triple therapy the prognosis for feline tuberculosis appears to be closer to 70-80% 323	
success when treating cutaneous and/or pulmonary tuberculosis caused M. bovis or M. microti (DGM and COH, 324	
unpublished data 2016). Prolonged therapy is therefore recommended in all cases, and due care is required 325	
when advising clients on discontinuing treatment.  326	
The majority of the cases in this series (cases 1, 4, 5, 7 and 8) demonstrated that where improvement in 327	
previously detected abnormalities can be identified on the basis of follow-up CT, tapering or cessation of 328	
treatment could be undertaken with greater confidence in the context of other clinical findings. However, for 329	
		 20	
some of the cases (6 and 9) significant changes remained at follow-up CT, despite the cats being clinically well, 330	
and as a result triple antibiotic therapy was continued.  331	
A previous study into the diagnostic and monitoring capacity of standard radiography in feline tuberculosis 332	
cases showed that with prolonged antibiosis, detectable pathology is eliminated in the vast majority of cases.4 333	
By comparison, in this case series some of the abnormalities detectable by CT imaging remained present in the 334	
majority of cases, though not all cats underwent repeat imaging following complete cessation of treatment. It is 335	
likely that this discrepancy partly results from the greater sensitivity of CT in comparison with radiography for 336	
detection of milder changes, highlighting its value. However this must be considered when repeat CT imaging 337	
is used to decide whether antibiotic treatment can be discontinued; complete resolution of pulmonary pathology 338	
cannot be reliably anticipated, even with extended antibiosis. This highlights the value of ongoing follow up 339	
imaging to document the lack of progression of changes, which can then be considered clinically incidental. 340	
In some cats undergoing treatment for feline tuberculosis, periods of clinical and/or radiological remission can 341	
be followed by recurrence of clinical signs, sometimes on multiple occasions (as seen in cases 1 and 3). It is 342	
difficult to determine if this represent recrudescence of disease following subclinical infection (latency) in the 343	
intervening periods, or reinfection. For example, cats who are habitual hunters have repeated exposure to a 344	
population of infected prey (as is the case for the cat in case 1). The return of clinical disease may be associated 345	
with extremely subtle clinical signs (as in case 1). The associated CT abnormalities may be similarly subtle (as 346	
in Figure 1c), but when a radiologically normal appearance has been documented during the remission period, 347	
these subtle changes can be considered significant, allowing for prompt reintroduction of treatment. This case 348	
also demonstrates the importance of careful and dedicated patient observation on the part of the owners; 349	
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monitoring sleeping respiratory rate is recommended in all cases of feline tuberculosis when undergoing 350	
treatment, even when there was initially no respiratory involvement.  351	
When repeating diagnostic procedures, it is important to evaluate the potential benefit to the patient, in relation 352	
to the costs involved. In the cases in this series we feel that the major benefit is clear; namely that the decision 353	
to either reduce/discontinue or restart treatment could be made with greater confidence. With reference to CT 354	
examination, a number of costs should be considered. The risk of repeated radiation exposure during scanning 355	
is one. We feel that in a population largely consisting of middle-aged cats the risk is minimal, though it should 356	
not be entirely discounted, particularly in cases where large numbers of repeated scans are performed. The 357	
effect of sedation or general anaesthesia should also be considered. Within a referral hospital the risks of these 358	
are low, 30 but they may warrant consideration particularly in clinically unstable patients with significant 359	
multisystem disease. Finally, the financial cost to the owner should also be considered. In several of the cases 360	
in this series, some of the associated costs and risks were reduced by use of a VetMouseTrap device, which 361	
allows for full body scanning in a non-sedated patient. Despite a slight reduction in sensitivity arising from a 362	
reduction in image resolution, this technique provides a very useful relatively low cost and non-invasive option. 363	
Notwithstanding the use of a VetMouseTrap device, in many referral centres the cost to the owner of a CT 364	
examination, either thorax in isolation or multiple body regions, does not significantly exceed that of full 365	
radiological examination. In addition, as CT becomes more widespread in non-specialist practice, its advantage 366	
as far as increased sensitivity over radiology warrants further consideration.  367	
Conclusions 368	
The cases described in this case series demonstrate the value of repeat CT imaging in the management of 369	
mycobacterial disease. When considered in combination with clinical findings, CT studies can aid in decision 370	
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making regarding tapering of antibiotic protocols, or reintroduction of therapy in cases of recurrence or 371	
reinfection. These cases also highlight that in some cases, persistent abnormalities can be detected by CT, which 372	
may not necessarily indicate an active disease process, and care should be taken in the interpretation of these 373	
findings.                   374	
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Figure captions: 457	
 458	
Figure 1. The CT appearance of lung parenchyma in case 1 at the level of the accessory lung lobe on three 459	
different occasions. (a) Diffuse, moderate reticulonodular pattern identified on the first occasion of disease 460	
recurrence following eleven months of clinical remission. (b) Normal pulmonary appearance three months 461	
later following triple antibiotic therapy and calcitriol supplementation. (c) Diffuse, mild reticular pattern 462	
noted concurrent with an increased sleeping respiratory rate but normal clinical examination, indicative of 463	
probable tuberculosis recurrence/relapse eleven months after image a. 464	
 465	
Figure 2. A timeline of diagnostic investigations and treatment for case 1; a seven year old male neutered 466	
Oriental cat with pulmonary TB caused by Mycobacterium microti.  467	
Rad – radiograph; TB – tuberculous changes; NAD – no abnormalities detected; mn – months; T – 468	
treatment; R – rifampicin; A – azithromycin; M – marbofloxacin; V – vitamin D; P – pradofloxacin; TB? 469	
– potentially tuberculous changes. 470	
 471	
Figure 3. The CT images at the level of the third sternebra from case 2 on two different occasions. (a) 472	
Image acquired four months after cessation of antibiotic therapy for disseminated tuberculosis showing an 473	
enlarged cranial mediastinal lymph node (*). (b) Image acquired five months later, showing a static 474	
appearance of the lymph node but a mild ground glass appearance of the adjacent lung parenchyma (arrow) 475	
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indicative of regional extension of disease. The cat was concurrently diagnosed with a mandibular 476	
squamous cell carcinoma.  477	
 478	
Figure 4. A timeline of diagnostic investigations and treatments for cases 2-9.  479	
Rad – radiograph; US – ultrasound; TB – tuberculous changes; NAD – no abnormalities detected; mn – 480	
months; T – treatment; R – rifampicin; A – azithromycin; M – marbofloxacin; C - clarithromycin V – 481	
vitamin D; P – pradofloxacin; TB? – potentially tuberculous changes; Euth – euthanasia; SCC – squamous 482	
cell carcinoma; No – no treatment given; Sx – surgery; MN – male neutered; FN – female neutered; DSH 483	
– domestic short haired; BSH – British short haired. 484	
 485	
Figure 5. The CT appearance of the lung parenchyma in case 4 at the level of the accessory lung lobe on 486	
two different occasions. (a) Multifocal regions of alveolar pattern with associated pulmonary cavitation (*) 487	
identified at initial presentation. (b) Follow up imaging after right caudal lung lobectomy and eight months 488	
of antibiotic treatment shows residual patchy ground glass appearance and collapsed pulmonary cavities 489	
(arrow). An additional CT study performed four months’ post surgery (not shown) showed very similar 490	
residual changes.  491	
 492	
Figure 6. The CT appearance of the lung parenchyma in case 5 at the level of the accessory lung lobe on 493	
two different occasions. (a) Marked, diffuse nodular lung pattern with occasional foci of mineralisation 494	
(arrows) identified at initial presentation. (b) Follow up imaging after eight months of treatment shows a 495	
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persistent mild reticulonodular pattern with mildly more extensive parenchymal mineralisation (arrow). 496	
Treatment was discontinued and a static appearance was recorded 12 months later, indicating these 497	
persistent changes do not reflect active disease. 498	
		
 
Figure 1. CT appearance of lung parenchyma in case 1 at the level of the accessory lung lobe on three different 
occasions. (a) Diffuse, moderate reticulonodular pattern identified on the first occasion of disease recurrence 
following eleven months of clinical remission. (b) Normal pulmonary appearance three months later following 
triple antibiotic therapy and calcitriol supplementation. (c) Diffuse, mild reticular pattern noted concurrent with 
an increased sleeping respiratory rate but normal clinical examination, indicative of probable tuberculosis 
recurrence/relapse eleven months after image a. 
	
	
	
	
Figure 2. A timeline of diagnostic investigations and treatment for case 1; a seven year old male neutered 
Oriental cat with pulmonary TB caused by Mycobacterium microti.  
 
Rad – radiograph; TB – tuberculous changes; NAD – no abnormalities detected; mn – months; T – treatment; R 
– rifampicin; A – azithromycin; M – marbofloxacin; V – vitamin D;  
P – pradofloxacin; TB? – potentially tuberculous changes. 
	
	
	
	
	
	
	
Figure 3. CT images at the level of the third sternebra from case 2 on two different occasions. (a) Image 
acquired four months after cessation of antibiotic therapy for disseminated tuberculosis showing an enlarged 
cranial mediastinal lymph node (*). (b) Image acquired five months later, showing a static appearance of the 
lymph node but a mild ground glass appearance of the adjacent lung parenchyma (arrow) indicative of regional 
extension of disease. The cat was concurrently diagnosed with a mandibular squamous cell carcinoma.  
	
	
	
Figure 4. A timeline of diagnostic investigations and treatments for cases 2-9.  
 
Rad – radiograph; US – ultrasound; TB – tuberculous changes; NAD – no abnormalities detected; mn – months; 
T – treatment; R – rifampicin; A – azithromycin; M – marbofloxacin; C - clarithromycin V – vitamin D; P – 
pradofloxacin; TB? – potentially tuberculous changes; Euth – euthanasia; SCC – squamous cell carcinoma; No 
– no treatment given; Sx – surgery; MN – male neutered; FN – female neutered; DSH – domestic short haired; 
BSH – British short haired. 
	
	
	
	
Figure 5. CT appearance of the lung parenchyma in case 4 at the level of the accessory lung lobe on two 
different occasions. (a) Multifocal regions of alveolar pattern with associated pulmonary cavitation (*) identified 
at initial presentation. (b) Follow up imaging after right caudal lung lobectomy and eight months of antibiotic 
treatment shows residual patchy ground glass appearance and collapsed pulmonary cavities (arrow). An 
additional CT study performed four months’ post surgery (not shown) showed very similar residual changes.  
	
	
	
	
Figure 6. CT appearance of the lung parenchyma in case 5 at the level of the accessory lung lobe on two 
different occasions. (a) Marked, diffuse nodular lung pattern with occasional foci of mineralisation (arrows) 
identified at initial presentation. (b) Follow up imaging after eight months of treatment shows a persistent mild 
reticulonodular pattern with mildly more extensive parenchymal mineralisation (arrow). Treatment was 
discontinued and a static appearance was recorded 12 months later, indicating these persistent changes do not 
reflect active disease. 
